EZH2 and neoplasm: Using the same ovarian cancer model, Zou and colleagues showed that Ezh2 deficiency in T cells suppressed control of tumor progression [63], while combined Ezh2 and DNMT inhibitors improved the efficacy of anti-PD-1 therapy by increasing the production of CXCL9 and CXCL10 [60].